Jackson, Carlayne E.School of Medicine |
![]() |
After completing a Clinical Neurophysiology fellowship at UTHSCSA and beginning my career as a clinical investigator, I established my vision of establishing a comprehensive center for the management of patients with neuromuscular diseases. My goal was to develop a multidisciplinary clinic which would integrate Neurology, respiratory therapy, physical therapy and occupational therapy. Over time, these efforts led to the development of the South Texas ALS Clinic. The clinic was awarded designation by the National ALS Association as an ALS Center of Excellence in 1996 and has retained this status since that time. The clinic is currently conducted at the MARC on Wednesday afternoons and provides care for approximately 200 ALS patients and their families throughout South and Central Texas. It is one of two centers in the State of Texas and one of only 34 in the United States. The UTHSCSA ALSA Center of Excellence provides something that is difficult to find in health care today: coordinated, efficient, multi-disciplinary care centered on the person with ALS and his or her family. It offers a multidisciplinary approach to treating the disease with symptomatic relief, prevention of complications, and maintenance of optimal independence. Under my leadership, the ALS team has grown and currently includes specialists from seventeen different disciplines to help treat these patients: Neurologist; Registered Research Nurse; Respiratory Therapist; Occupational Therapist; Physical Therapist; Registered Dietician; Pastoral Care; Social Worker; Assistive Technology Specialist; Medical Equipment Specialist; Respiratory Therapy Educator; Amyotrophic Lateral Sclerosis Association South Texas Patient Services; Gastroenterologist; Pulmonologist; Orthotist; Speech Pathologist; and Psychiatrist. Together, our team develops an individualized care plan in response to each patient?s specific needs. The accessibility of the team for questions and help, the attention to needs and details, the ability to anticipate problems and help solve troubling billing and insurance issues, and the commitment to prepare people with ALS ahead of time for probable changes so that the are ready ? these all mean that no one has to feel alone on the journey. I am particularly proud of the fact that our team provides an incomparable level of expertise in ALS and is now considered one of the top ALS centers in the country.
|
4/2009 - Present | Chief Medical Officer | UT Medicine, San Antonio, TX |
5/2008 - Present | Assistant Dean of Ambulatory Services and Other | UTHSCSA, San Antonio, TX |
7/2007 - Present | Professor w/Tenure | UTHSCSA, Oto-Hns, San Antonio, TX |
9/2001 - Present | Professor w/Tenure | UTHSCSA, Dept of Neurology, San Antonio, TX |
7/1991 - Present | Staff Neurologist | Bexar County Hospital District, Medicine, San Antonio, TX |
Year | Degree | Discipline | Institution |
1987 | MD | Medicine | UTHSCSA San Antonio , TX |
1983 | BS | Chemical Engineering | Texas A&M University College Station , TX |
Residency | Neurology | UTHSCSA San Antonio , TX |
|
Internship | Internal Medicine | UTHSCSA San Antonio , TX |
|
Postdoctoral Fellowship | Neurophysiology | UTHSCSA San Antonio , TX |
Neuromuscular Specialist- Clinical trials of a wide variety of potential therapies for inclusion body myositis, amyotrophic lateral sclerosis, myasthenia gravis, and peripheral neuropathy. |
Date | Description | Institution | # Students |
9/2002 - Present | Clinical Medicine | The University of Texas Health Science Center | |
Occupational Therapy Clinical Series, "ALS" | |||
9/2001 - Present | Intro to Clin Medicine | The University of Texas Health Science Center | |
"Myopathy" | |||
9/1999 - Present | Research Neurology Select | The University of Texas Health Science Center | |
ACES Neurology Lab | |||
9/1996 - Present | Special Topic | The University of Texas Health Science Center | |
Neuromuscular Journal Club | |||
1/1996 - Present | Clinical Medicine | The University of Texas Health Science Center | |
South Texas ALS Clinic | |||
9/1994 - Present | Clinical Medicine | The University of Texas Health Science Center | |
Neuromuscular Service Attending | |||
9/1993 - Present | Intro to Clin Medicine | The University of Texas Health Science Center | |
"Amyotrophic Lateral Sclerosis" | |||
9/1993 - Present | Intro to Clin Medicine | The University of Texas Health Science Center | |
"Myasthenia Gravis" | |||
9/1991 - Present | Clinical Medicine | The University of Texas Health Science Center | |
Inpatient Consult Service, University and VA Hospitals | |||
9/1991 - Present | Clinical Medicine | The University of Texas Health Science Center | |
Neurology Faculty Back-up Call | |||
1/1991 - Present | Clinical Medicine | The University of Texas Health Science Center | |
Muscular Dystrophy Association |
Abstract |
Jackson CE, Rudnicki SA, Andrews JA, Genge A, Lechtzin N, Malik FI, Miller T, Wolff AA, Shefner JM. A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study of Reldesem tiv in Patients With Amyotrophic Lateral Sclerosis (FORTITUDE-ALS); 2018 Mar. (Presented at the 2018 MDA Clinical Conference). |
Agarwal T, Bhavaraju-Sanka R, Jackson CE. Unusual Cause of Childhood Onset Ptosis and Opthalmoplegia: Wolters Kluwer; 2018 Mar. (Clinical Neuromuscular Disease; vol. 19, no. 3). |
Jackson CE,de Carvalho M, Genge A, Heiman-Patterson T, Shefner J, Wel Jenny, Wolff AA. Relationships Between Slow Vital Capacity and Measures of Respiratory; 2017 Dec. (Presented at the 2017 ALS/MND Symposium). |
Bokov AF, Olin GP, Bos A, Tirado-Ramos A, Kittrell P, Jackson CE. Exhaustively Characterizing a Patient Cohort by Prevalence of EMR Facts: A Generalized, Vendor-Agnostic Method for Quality Control and Research; 2017 Nov. (AMIA Annual Symposium Proceedings). |
Clegg A, Morse S, Quiroz L, Jackson CE, Jones K, Kittrell P, MArtin K, Myers D, Ortiz F, Tyler L, Wettstein R. Improving Healthcare Professionals' Self-Efficacy Through An Interprofessional Continuing Education Program About ALS; 2017 Nov. (Presented at the 2017 Association of Schools of Allied Health Professions). |
Heberlin L, Statland J, Kimminau K, McMahon T, Adagarla B, Barkhaus P, Jackson CE, Walk D, Fernandes A, Trivedi J, Goebel S, Waclawik A, Boero J, Swenson A, Waitman, Barohn R; GPC ALS Investigators. Patient Activity of Daily Living for Amyotrophic Lateral Sclerosis (S13.007); 2017 Apr. (Neurology; vol. 88, no. 16). |
Heiman-Patterson T, Cudkowicz M, de Carvalho M, Genge A, Hardiman O, Jackson C, Lechtzin N, Mitsumoto H, Silani V, Rudnicki SA, Kulke S, Andrews JA, van den Berg LH. Understanding The Use of Noninvasive Ventilation In The Treatment of Amyotrophic Lateral Sclerosis In The US and Europe: Results of an International Physician Survey(P5.071); 2017 Apr. (Neurology; vol. 88, no. 16). |
Jackson CE, George A, Sherman M, Verma A, Shefner J, Scelsa S, Newman D, E Kasarskis, Heiman-Patternson T. Early Treatment With NIPPV: Factors Affecting Compliance Over Time: Taylor & Francis; 2016 Dec. (ALS and Frontotemporal Degeneration, Abstracts from the 27th International Symposium on ALS/MND; vol. 17, no. 1). |
Barohn RJ, Statland J, Moore D, Walsh M, Mozaffar T, Elman L, Nations S, Hitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, WALS Rasagiline 80 Study Group. Rasagiline For The Treatment of ALS: A Randomized Controlled Study; 2016 Nov. (Abtract presentation at the 27th International Symposium on ALS/MND, Dublin Ireland; vol. 1, no. S1). |
Jackson CE, Stuart Isaacson, Lawrence Severt, Jean Hubble, Thomas Clinch. MYSTICOL: A Randomized, Controlled Study of Myobloc in the Treatment of Sialorrhea for Amyotrophic Lateral Sclerosis (ALS) and Neurological Conditions: http://www.alsconsortium.org; 2016 Oct. |
Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson CE, Swenson A, Howard JF, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfield J, Dimachkie MM, Statland JM, Barohn RJ. A Randomized Controlled Trial of Methotrexate for Patients with Geralized Myasthenia Gravis; 2016 Mar. (Neurology; vol. 87, no. 1). |
Jackson CE, Lotz G, Jasko J, Boyce C, Schroth M, Jackson L, Kittrell P. Evaluation of the CoughAssist E70 compared to Cough assist 3000 in Adults with Amyotrophic Lateral Sclerosis; 2014 Dec. (Presented at the 25th Annual International Symposium on ALS/MND; Brussels, Belgium). |
Gardner D, Jackson L, Kittrell P, Walden CE, Jackson CE. ALS and Airway Clearance (ALSAC); Is there a best therapy for airway clearance in patients with ALS?; 2014 Dec. (Presented at the 25th Annual International Symposium on ALS/MND; Brussels, Belgium). |
Kittrell P, Tobon A, Fincke C, Motazedi T, Jackson CE. Safety of Peg Tube Insertion in Patients with ALS Using Propofol Sedation in an Outpatient Surgical Setting; 2014 Dec. (Presented at the 25th Annual International Symposium on ALS/MND; Brussels, Belgium). |
Tandan R, Boylan K, Levine T, Lomen-Hoerth C, Callas P, Maginnis K, Lyon M, ALS Cost Study Group. Prospective Study of Cost of Care at Multidisciplinary Centers Adhering to American Academy of Neurology (AAN) ALS Practice Parameters (S49.001); 2014 Apr. (Neurology; vol. 82, no. 10). |
Shefner J, Andrews J, Bedlack R, Berry J, Goslin K, Jackson C, Kissel J, Lange D, Licht J, Mozaffar T, Pestronk A, Rosenfeld J, Wolff A, Lee J, Masonek J, Jones D, Meng L, Cedarbaum J. A Study to Evaluate Safety and Tolerability of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis Using a Twice-Daily, Dose-Titration Regimen; 2012 Apr. (Neurology; vol. 78, no. 1). |
Rawson, J, Grogan P, Jackson CE, Chao W, Torres K. Early Onset Ocular, Facial and Limb Weakness with High CK; 2011 Mar. (Clinical Neuromuscular Disease; vol. 12, no. 3). |
Rosenfeld J, Chang SW, Jackson CE, Elchami Z, Barohn RJ. Lower extremity amyotrophic diplegia (LAD): A new clinical entity in the spectrum of motor neuron disease; 2002 Jan. (Neurology; vol. 58, no. 3). |
Book Chapter |
Jackson CE. Neuromuscular Diseases: Disorders of the Motor Neuron and Plexus and Peripheral Nerve Disease. In: Benjamin I, Griggs R, Wing E, Fitz J. Andreoli and Carpenter`s Cecil Essentials of Medicine. 2015. p. 1077-1086. |
Rosenfeld J, Jackson CE. Outcome Measures and Clinical Assessment Instruments in Neuromuscular Disease. In: Katirji B, Kaminski H, Preston D, Ruff R, Shapiro B (eds). Neuromuscular Disorders in Clinical Practice. New York,NY: Springer; 2014. |
Journal Article |
Heiman Patterson T, Cudkowicz M, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews J, Chen D, Kulke S, Rudnicki S, Van Den Berg L. Understanding The Use of NIV In ALS: Results of An International ALS Specialist Survey Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (ACCEPTED) 2018 Apr;. |
Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, Andrews J for the BENEFIT-ALS Study Group. Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS (BENEFIT-ALS): A Randomized, Placebo-Controlled, Double-Blind Phase 2b Trial Evaluating Safety and Efficacy of Tirasemtiv In Patients With ALS Amyotroph Lateral Scler Frontotemporal Degener 2016 Aug;17(5-6). |
Wolfe GI, Kaminski HJ, Aba? IB, Minispan G, Kuo HC, Marx A, Strobel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Wisoonpanich R, King JO, Beydoun SR, Chalk CH, Katirji B, Lecky BR, Buckley C, Vincent A, Diaz-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley M, Rivner MH, Kostera-Pruszcyzyk A, Pacuzzi RM, Jackson CE, Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Baron RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett R, Jaretzki A, Newsom-Davis J, Cutter GR, MGTX Study Group. Randomized Trial of Thymectomy in Myasthenia Gravis The New England Journal of Medicine 2016 Aug;375(6):511-522. |
Macchi Z, Wang Y, Moore D, Katz J, Saperstein D, Walk D, Simpson E, Genge A, Bertorini T, Fernandes JA, Swenson A, Elman L, Dimachkie M, Herbelin L, Miller J, Lu J, Wilkins H, Swerdlow RH, Statland J, Barohn R; Western ALS (WALS) Rasagiline Study Group. A Multi-Center Screening Trial of Rasagiline In Patients With Amyotrophic Lateral Sclerosis: Possible Mitochondrial Biomarker Target Engagement Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2015 Sep;16(5-6):345-352. |
Carr KR, Shah M, Garvin R, Shakir A, Jackson CE. Post-Traumatic brain injury (TBI) presenting with Guillain-Barre syndrome and elevated anti-ganglioside antibodies: a case report and review of the literature International Journal of Neuroscience 2015 Jul;125(7). |
Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Bromber M, Kryscio RJ, ALS Nutrition/NIPPV Study Group. Estimating Daily Energy Expenditure in Amyotrophic Lateral Sclerosis American Journal Clinical Nutrition 2014 Apr;99(4):792-803. |
Jackson CE, Barohn RJ. A Pattern Recognition Approach To Myopathy Continuum (Minneap Minn) 2013 Dec;6:1674-1697. |
Miller RG, Brooks BR, Swain-Eng RJ, Basner RC, Carter GT, Casey P, Cohen AB, Dubinsky R, Forshew D, Jackson CE, Kasarskis E, Procaccini NJ, Sanjak M, Tolin FP. Quality Improvement In Neurology: Amyotrophic Lateral Sclerosis Quality Measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology Neurology 2013 Nov;81(24):2136-2140. |
Cudkowicz ME, Van Den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AD, Dong Y, Farwell WR, Kerr DA, the EMPOWER Investigators. Dexpramipexole Versus Placebo For Patients With Amyotrophic Lateral Sclerosis (EMPOWER): A Randomised, Double-Blind, Phase III Trial The Lancet Neurology 2013 Nov;13(1):1059-1067. |
Dimachkie MM, Muzyka IM, Katz JS, Jackson CE, Wang Y, McVey A, Dick A, Pasnoor M, Mozaffar MT, Xiao-Song Z, Kissel JT, Ensrud E, Rosenfeld J, Barohn RJ. Leg Amyotrophic Diplegia: Prevalence and Pattern of Weakeness at US Neuromuscular Centers Journal of Clinical Neuromuscular Disease 2013 Sep;15(1):7-12. |
Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn RJ, Muscle Study Group. Phase II Trial of Methotrexate in Myasthenia Gravis Annals of New York Science Academy 2012 Dec;1275:23-28. |
Wagner L, Archer NP, Williamson DM, Henry JP, Schiffer R, Jackson CE. Prevalence of Amyotrophic Lateral Sclerosis in Texas, 1998-2003 Texas Medicine 2012 May;108(5). |
Federal |
|
Funding Agency | National Institute of Health |
Title | Characterization of Agin/LRP4 Antibody-Positive Myasthenia Gravis |
Status | Active |
Period | - Present |
Role | Co-Principal Investigator |
Grant Detail | |
Funding Agency | NINDS |
Title | A Phase II Trial of Rituximab in Myasthenia Gravis |
Status | Active |
Period | 5/2014 - 12/2017 |
Role | Consultant |
Grant Detail | The specific primary objective of this trial is to determine whether rituximab is a safe and beneficial therapeutic for MG that warrants further study in a phase III efficacy trial. |
Funding Agency | University of Miami / NIH |
Title | Clinical Research In ALS |
Status | Active |
Period | 7/2015 - 6/2016 |
Role | Co-Investigator |
Grant Detail | PHENOTYPE, GENOTYPE, AND BIOMARKERS (PGB) IN ALS AND RELATED DISORDERS The PGB protocol aims to (a) identify the phenotypic correlates of genotype; (b) discern the genetic contributions to phenotype; and (c) develop and validate biomarkers of relevance to therapeutic development for ALS and related disorders. Lay a firm foundation for future clinical trials in relatively homogeneous subsets of patients with ALS and related disorders and defined genetic etiologies. This objective includes the development of a contact registry that includes individuals who might be eligible for future clinical trials. |
Private |
|
Funding Agency | ALS Association, MDA, Synapse Biomedical Inc |
Title | Multi-Center, Randomized Controlled Study of the NeuRx Diaphragm Pacing System (DPS) In Participants with Amyotrophic Lateral Sclerosis (ALS) |
Status | Active |
Period | 11/2014 - Present |
Role | Principal Investigator |
Grant Detail | The goal of this study is to compare the diaphragm pacing system (DPS) with no DPS in patients with ALS and hypoventilation while looking at improved survival or diaphragm function. |
Funding Agency | Solstice Neurosciences, LLC |
Title | A Phase III Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC (Part A) Followed by Open-Label, Multiple-Treatments with MYOBLOC (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects (MYST |
Status | Active |
Period | 6/2013 - Present |
Role | Principal Investigator |
Grant Detail | The goal of this study is to compare safety and tolerability of MYOBLOC vs placebo in the treatment of troublesome sialorrhea in adult subjects. |
Funding Agency | Cytokinetics, Inc. |
Title | A Phase II, Multi-Center Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study To Evaluate The Efficacy, Safety, and Tolerability of CK-2127107 In Patients With Amyotrophic Lateral Sclerosis (ALS) |
Status | Active |
Period | 8/2017 - 8/2019 |
Role | Principal Investigator |
Grant Detail | |
Funding Agency | Neuraltus Pharmaceuticals, Inc |
Title | A Phase 2 Randomized, Double-Blind, Pacebo-Controlled, Multicenter Study of NP001 In Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation |
Status | Active |
Period | 1/2017 - 12/2018 |
Role | Principal Investigator |
Grant Detail | |
Funding Agency | Amylyx Pharmaceuticals, Inc. |
Title | Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, A Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), For Treatment of Amyotrophic Lateral Sclerosis (ALS) |
Status | Active |
Period | 2/2017 - 1/2018 |
Role | Principal Investigator |
Grant Detail | |
Funding Agency | Cytokinetics, Inc. |
Title | A Phase 3, Open-Label Extnesion Study of Tirasemtiv For Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031) |
Status | Active |
Period | 1/2017 - 12/2017 |
Role | Principal Investigator |
Grant Detail | |
Funding Agency | Cytokinetics, Inc. |
Title | Protocol CY 4031- A phase 3 Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS). |
Status | Active |
Period | 7/2015 - 6/2017 |
Role | Co-Investigator |
Grant Detail | Product Name: tirasemtiv. Endura CT Number 2014-005413-23 |
Funding Agency | Questcor-Pharmaceuticals Inc. |
Title | A Study To Explore The Safety and Tolerability of Acthar In Patients With Amyotrophic Lateral Sclerosis |
Status | Complete |
Period | 1/2014 - 12/2016 |
Role | Principal Investigator |
Grant Detail | The goal of this study is to investigate the safety and tolerability of 4 different doses of Acthar in ALS patients. |
Funding Agency | Solstice Neurosciences, LLC |
Title | A Phase III, Long Term, Open-Label and Single Arm Study of Myobloc In The Treatment of Troublesome Sialorrhea In Adult Subjects |
Status | Active |
Period | 10/2015 - 9/2016 |
Role | Principal Investigator |
Grant Detail | To determine the efficacy of MYOBLOC? (as a single total dose of 2,500 Units or 3,500 Units) versus placebo in the treatment of troublesome sialorrhea in adult subjects .To compare the safety and tolerability of MYOBLOC? versus placebo. |
Funding Agency | Biogen Idec Inc |
Title | An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects with Amyotrophic Lateral Sclerosis (ALS) |
Status | Complete |
Period | 6/2012 - 5/2015 |
Role | Co-Investigator |
Grant Detail | The goal of this open label study is to evaluate the long-term safety profile of dexpramipexole in subjects with ALS. |